A novel subset of hepatocytes is simultaneously gluconeogenic and de novo lipogenic in the fed state and is naturally insulin resistant

This study challenges the traditional view of mutually exclusive hepatic metabolic states by identifying a novel, naturally insulin-resistant subset of periportal hepatocytes that simultaneously perform gluconeogenesis and de novo lipogenesis in the fed state, a phenomenon that expands in high-fat diet conditions and suggests a new paradigm for understanding liver insulin resistance.

The Gist

The Big Idea: The Liver's "Double-Shift" Workers

Imagine your liver is a massive, bustling factory. For decades, scientists believed this factory had two distinct shifts with strict rules:

1. The Night Shift (Fasting): When you haven't eaten, the factory workers (hepatocytes) stop making new products and switch to making glucose (sugar) to keep your blood sugar up.
2. The Day Shift (Fed): When you just ate a meal, the workers stop making sugar and switch to making fat (lipogenesis) to store the extra energy.

The old rule was: You can't do both at the same time. It was like a factory that either only baked bread or only built cars, never both in the same room.

This paper discovered a secret group of workers who break the rules. They are a small subset of liver cells that, even right after you eat, are simultaneously making sugar AND making fat. Even stranger, these workers are naturally "stubborn" and ignore the boss's orders to stop making sugar.

---

The Detective Work: How They Found Them

The researchers used high-tech "microscopes" and "cameras" to look inside the liver of mice. Here is how they did it:

• The Single-Cell Camera (scRNA-seq): Instead of looking at the whole liver as a blur, they took a photo of every single cell individually. They found a tiny group of cells (about 7-12% of the liver's front-line workers) that had the blueprints for both sugar-making and fat-making active at the same time.
• The Fluorescent Highlighters (RNA-FISH): They used glowing markers to light up the specific genes inside the cell nuclei. They saw that in some cells, the "Sugar Light" and the "Fat Light" were both glowing bright green and pink at the exact same time.
• The Energy Tracker (ATP Imaging): Making both sugar and fat requires a lot of energy (like a car engine revving high). They used special imaging to see where the most energy was being burned. They found "hot spots" in the liver where the energy consumption was through the roof, confirming these cells were doing double duty.

The "Stubborn" Workers: Natural Insulin Resistance

Here is the most surprising part.

In a healthy body, when you eat, your pancreas releases insulin. Think of insulin as the Factory Manager who walks in and says, "Stop making sugar! We have plenty of food coming in. Just make fat and store it!"

Usually, the liver listens immediately. But this special group of "Dual-Modal" workers? They ignore the Manager.

Even when insulin is flooding the system, these specific cells keep making sugar. The researchers call this "natural insulin resistance." It's not a disease yet; it's just how these specific cells are built. They are like a stubborn employee who keeps working on a project even after being told to stop.

Why Does This Matter?

1. The "Basal" Sugar Leak:
Scientists used to think the tiny amount of sugar the liver made while you were eating was just "background noise" or a mistake. This paper says: No, it's intentional. It's a specific team of workers keeping a low-level sugar production line running, perhaps as a safety net to ensure your brain always has a little fuel, even when you are full.

2. The Link to Diabetes:
The researchers fed mice a high-fat diet (like a junk-food diet for humans). They found that the number of these "stubborn, double-working" cells increased significantly.

• The Analogy: Imagine a factory where a few stubborn workers ignore the manager. That's fine. But if the factory hires more of these stubborn workers because of a bad diet, suddenly the whole factory is making too much sugar when it shouldn't. This leads to high blood sugar and Type 2 Diabetes.

The Human Connection

The team even looked at "humanized" mouse livers (mice with human liver cells). They found the same "stubborn double-workers" there. This suggests that humans have this same hidden mechanism, and understanding it could help us figure out why some people become insulin resistant and develop diabetes.

Summary in a Nutshell

• Old Belief: The liver switches off sugar-making when you eat.
• New Discovery: A small, special team of liver cells keeps making sugar and fat at the same time, even when you are full.
• The Problem: These cells ignore the "stop" signal from insulin.
• The Danger: Eating a bad diet makes this stubborn team grow bigger, which can lead to diabetes.

This paper changes how we see the liver: it's not just a switch that flips on and off; it's a complex factory with a specialized, stubborn team that might be the key to understanding metabolic disease.

Technical Summary

1. Problem Statement

The prevailing dogma in hepatic metabolism posits a strict temporal and spatial separation of metabolic pathways:

• Fed State: The liver is primarily lipogenic (synthesizing fatty acids) and suppresses gluconeogenesis (glucose production) via insulin signaling.
• Fasted State: The liver is primarily gluconeogenic and suppresses lipogenesis.
• Zonation: Periportal (PP) hepatocytes are traditionally associated with gluconeogenesis and urea synthesis, while pericentral (PC) hepatocytes are associated with glycolysis and lipogenesis.

However, clinical data (e.g., hyperinsulinemic-euglycemic clamps) consistently show a non-zero basal rate of hepatic glucose production (HGP) even in the fed state under high insulin levels. The molecular and cellular basis for this "basal" gluconeogenesis, and how it co-exists with active lipogenesis, has remained unexplained. This study challenges the binary view of hepatic metabolism by investigating whether a specific subpopulation of hepatocytes can simultaneously perform these opposing functions.

2. Methodology

The authors employed a multi-modal, high-resolution approach combining transcriptomics, spatial imaging, stable isotope tracing, and metabolic flux analysis:

• Targeted Single-Cell RNA Sequencing (scRNA-seq): Used the 10x Genomics platform to profile metabolic gene expression in isolated hepatocytes from fed and fasted mice to identify co-expression patterns.
• RNAPII ChIP-seq: Assessed RNA Polymerase II occupancy to determine transcriptional activity (active transcription vs. paused) of gluconeogenic (Pck1, G6pc) and lipogenic (Fasn, Acly) genes in total, periportal (PP), and pericentral (PC) hepatocytes.
• HCR RNA-FISH (Hybridization Chain Reaction): Visualized transcription sites (TS) of Fasn and Pck1 simultaneously within individual nuclei in liver sections to confirm co-transcription.
• PrimeFlow RNA Assay: Combined in situ hybridization with flow cytometry to quantify the percentage of dual-positive (Fasn+/ Pck1+) hepatocytes and test their response to insulin suppression.
• Stable Isotope Tracing & Metabolic Flux:
  • Deuterium Oxide ($^2$H$_2$O): Traced de novo lipogenesis (palmitate synthesis).
  • $^{13}$C-Pyruvate: Traced gluconeogenesis (glucose synthesis) in isolated PP and PC hepatocytes.
• Spatial Metabolic Imaging (DESI & MALDI MSI): Used mass spectrometry imaging with $^{18}$O-labeled water (to measure ATP turnover) and U[$^{13}$C]-glucose (to trace metabolic flux) to visualize simultaneous lipogenesis and gluconeogenesis at the single-cell level in tissue sections.
• Euglycemic-Hyperinsulinemic Clamps: Performed in vivo to test the insulin sensitivity of the dual-positive hepatocyte population compared to the bulk liver.
• Humanized Mouse Models: Utilized uPA-SCID mice with human hepatocyte repopulation to validate findings in human liver tissue using Visium spatial transcriptomics.

3. Key Contributions & Results

A. Discovery of "Dual-Modal" (DM) Hepatocytes

• Co-expression: In the fed state, a specific subset of periportal (PP) hepatocytes simultaneously expresses both lipogenic genes (Fasn, Acly, Elovl6) and gluconeogenic genes (Pck1, G6pc).
• Transcriptional Activity: RNAPII ChIP-seq and HCR RNA-FISH confirmed that these genes are not just present as mRNA but are actively transcribed (transcription sites detected) in the same nucleus.
• Prevalence: Approximately 7–24% of periportal hepatocytes in the fed state are dual-positive, depending on the detection method (scRNA-seq vs. FISH).

B. Functional Metabolic Duality

• Simultaneous Flux: Isolated PP hepatocytes in the fed state showed significant rates of both de novo lipogenesis (palmitate synthesis) and gluconeogenesis (glucose production from pyruvate).
• Spatial Confirmation: Mass spectrometry imaging (DESI/MALDI) using U[$^{13}$C]-glucose revealed individual hepatocytes containing both labeled palmitate (lipogenesis) and labeled glucose-6-phosphate (gluconeogenesis).
• Energetic Demand: These dual-positive regions exhibited significantly higher ATP turnover (measured via $^{18}$O exchange) compared to bulk hepatocytes, consistent with the high energy cost of running opposing pathways.

C. Natural Insulin Resistance

• Insulin Suppression: While bulk hepatocytes suppress Pck1 expression rapidly in response to insulin, the dual-positive (DM) hepatocytes are naturally insulin resistant.
• Clamp Data: In euglycemic-hyperinsulinemic clamps, Pck1 mRNA in the dual-positive population was not suppressed until insulin infusion rates reached 2 mU/kg/min, whereas the bulk liver suppressed at much lower rates (0.3 mU/kg/min).
• Mechanism: This suggests these cells are intrinsically resistant to insulin's ability to shut down gluconeogenesis, even in the presence of high insulin and lipogenic substrates.

D. Pathophysiological Relevance

• High-Fat Diet (HFD): In mice fed a high-fat diet for 3 months, the proportion of dual-positive hepatocytes increased from 4% (Normal Chow) to **13%**.
• Human Relevance: Spatial transcriptomics on humanized mouse livers confirmed the existence of similar dual-positive spots in human hepatocytes, suggesting this is a conserved physiological feature.

4. Significance

• Paradigm Shift: The study overturns the classical view that gluconeogenesis and lipogenesis are mutually exclusive in the fed state. It identifies a specific, naturally insulin-resistant hepatocyte subpopulation that drives basal hepatic glucose output despite high insulin levels.
• Mechanism of Insulin Resistance: The authors propose that the expansion of this "Dual-Modal" population under metabolic stress (e.g., HFD) is a primary driver of hepatic insulin resistance and persistent hyperglycemia in type 2 diabetes, rather than just a generalized failure of insulin signaling in all hepatocytes.
• Therapeutic Implications: Targeting the specific expansion or metabolic regulation of this dual-positive subset could offer a novel therapeutic strategy to reduce hepatic glucose output without disrupting the necessary lipogenic functions of the liver in the fed state.
• Methodological Advance: The integration of spatial metabolomics with single-cell transcriptomics provides a powerful framework for resolving metabolic heterogeneity that bulk tissue analysis misses.

In summary, this paper identifies a distinct, naturally insulin-resistant subset of periportal hepatocytes that simultaneously perform gluconeogenesis and lipogenesis in the fed state, providing a cellular mechanism for basal hepatic glucose production and the progression of diet-induced insulin resistance.